The European Medicines Agency has begun operating in Amsterdam after being forced to leave London because of the UK’s exit from the EU.
Europe’s drug approval and safety agency began working out of the Spark building in Amsterdam Sloterdijk on 11 March, it has announced, after leaving its London office on 1 March. The building is a temporary measure, pending the completion of tailor-made premises in Amsterdam Zuidas.
However, some staff will telework from London until the second half of the year. The EMA said it expected close to 350 staff members to have relocated by 18 March, out of 900 in total. It still expects to have to replace about a quarter of its workforce due to the move.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.